CNS Infections Effect on the Inner Ear

Status Recruiting

Clinical Trial Summary

Study on patients with CNS infections.

Clinical Trial Description

Aims and objectives:

The present proposal aims to improve the outcome from central nervous system infections (CNS) by improving the understanding of when and why patients develop hearing loss and other neurological sequelae. The investigators will elucidate the temporal development and restitution of a sensorineural hearing loss and will clarify if any therapeutic window exists, where sequelae can be limited.

Also the investigators will investigate if communication between cochlea and cerebrospinal fluid is a window to the intracranial pressure.

Background:

CNS infections remain diseases with high mortality and morbidity. Among survivors from bacterial meningitis, 30 % suffer hearing loss or deafness arising from injury to the inner ear - the cochlea. From previous work it is known that brain inflammation, brain edema and subsequent pressure changes can be transduced to the inner ear due to communication between the cochlea and cerebrospinal fluid (CSF).

The viability of cochlear hair cells can evaluated by non-invasive measurement of otoacoustic (OAE) emissions which are low-intensity sounds from the cochlea (OAE).

Methods and materials:

The investigators will perform repeated measurements of OAE and Wide Band tympanometry (WBT) in all patients admitted with suspicion of a CNS infection. OAE and WBT will be compared to intracranial pressure (ICP) measured during lumbar puncture as well as clinical-, biochemical- and imaging data. An age-matched control group will be included. At discharge and at follow-up patients will receive a neurological, vestibulare examination, cognitive test and a regular hearing test.

Expected outcome and perspectives:

From repeated measures during a course of disease, the investigators will elucidate the development of a hearing loss and clarify if any therapeutic window exists, where sequelae can be limited. This is also an opportunity to assess OAE as a non-invasive measure of intracranial pressure which is believed to be among the clinical complications responsible for a poor outcome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03715569
Study type	Observational
Source	Nordsjaellands Hospital
Contact	Elisa Skovgaard Jensen, MD
Phone	+4530300969
Email	elisa.skovgaard.jensen@regionh.dk
Status	Recruiting
Phase
Start date	December 1, 2017
Completion date	December 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04281953` - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Not yet recruiting	`NCT05973669` - MED-EL Remote Care Multi-Center Feasibility Study	N/A
Completed	`NCT04601909` - FX-322 in Adults With Age-Related Sensorineural Hearing Loss	Phase 1
Active, not recruiting	`NCT04479761` - Sensory Integration of Auditory and Visual Cues in Diverse Contexts	N/A
Recruiting	`NCT05043207` - A Study Protocol for the Validation of UAud in a Clinical Setting.	N/A
Recruiting	`NCT04066270` - Inventory of Radiological and Vestibular Function in Cochlear Implant Candidates
Recruiting	`NCT04070937` - Correlation of Radiological Lesions With Vestibular Function in Patients With Bilateral Vestibulopathy
Completed	`NCT03512951` - Subjective Evaluation of a Sound Processing Method for Hearing Aids on Auditory Distance Perception	N/A
Completed	`NCT05855005` - Direct-to-Consumer Hearing Aids and Listening Effort	N/A
Recruiting	`NCT05599165` - Speech Perception in Bimodal Hearing	N/A
Completed	`NCT05101083` - Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids	N/A
Completed	`NCT05521308` - Investigating Hearing Aid Frequency Response Curves	N/A
Completed	`NCT05072457` - Benefit of Assistive Listening Device for Lateralization	N/A
Recruiting	`NCT05776459` - Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)	Phase 2
Completed	`NCT05086276` - FX-322 in Adults With Acquired Sensorineural Hearing Loss	Phase 2
Recruiting	`NCT06058767` - Preschool Hearing Screening	N/A
Completed	`NCT05180630` - Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems	N/A
Completed	`NCT03613909` - Acceptance of the CP950 Sound Processor	N/A
Active, not recruiting	`NCT03352154` - Long Latency Auditory Evoked Potentials (P300) Outcomes in Patients With Unilateral Cochlear Implants	N/A
Completed	`NCT04629664` - FX-322 in Adults With Severe Sensorineural Hearing Loss	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.